The glucagon-like peptide 1 analog liraglutide reduces TNF-α-induced oxidative stress and inflammation in endothelial cells

Atherosclerosis

Volumn 221, Issue 2, 2012, Pages 375-382

  Shiraki, Aya ^a   Oyama, Jun ichi ^a   Komoda, Hiroshi ^a   Asaka, Machiko ^a   Komatsu, Aiko ^a   Sakuma, Masashi ^a   Kodama, Kazuhisa ^a   Sakamoto, Yoshiko ^a   Kotooka, Norihiko ^a   Hirase, Tetsuaki ^a   Node, Koichi ^a  

^a SAGA UNIVERSITY   (Japan)

Author keywords

Apoptosis; Endothelial cell; Inflammation; NF B; Oxidative stress

Indexed keywords

CATALASE; GLUTATHIONE PEROXIDASE; I KAPPA B; I KAPPA B KINASE ALPHA; I KAPPA B KINASE BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIRAGLUTIDE; MANGANESE SUPEROXIDE DISMUTASE; PENTRAXIN 3; PROTEIN KINASE C ALPHA; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; TUMOR NECROSIS FACTOR ALPHA;

ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; APOPTOSIS; ARTICLE; CELL FRACTIONATION; ENDOTHELIAL DYSFUNCTION; ENZYME ACTIVATION; HEART PROTECTION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IMMUNOFLUORESCENCE MICROSCOPY; INFLAMMATION; INTRACELLULAR SIGNALING; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RECEPTOR UPREGULATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UMBILICAL VEIN ENDOTHELIAL CELL; WESTERN BLOTTING;

ANTI-INFLAMMATORY AGENTS; ANTIOXIDANTS; APOPTOSIS; C-REACTIVE PROTEIN; CATALASE; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; GLUCAGON-LIKE PEPTIDE 1; GLUTATHIONE PEROXIDASE; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; I-KAPPA B KINASE; I-KAPPA B PROTEINS; INFLAMMATION MEDIATORS; MEMBRANE GLYCOPROTEINS; NADPH OXIDASE; NF-KAPPA B; OXIDATIVE STRESS; PHOSPHORYLATION; PROTEIN KINASE C-ALPHA; PROTEIN TRANSPORT; REACTIVE OXYGEN SPECIES; RECOMBINANT PROTEINS; SERUM AMYLOID P-COMPONENT; SIGNAL TRANSDUCTION; SUPEROXIDE DISMUTASE; TIME FACTORS; TRANSFECTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84858707110     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2011.12.039     Document Type: Article

References (29)

1. Holst J.J. The physiology of glucagon-like peptide 1. Physiol Rev 2007, 87:1409-1439.
2. Ceriello A., Esposito K., Testa R., et al. The possible protective role of glucagon-like peptide 1 on endothelium during the meal and evidence for an endothelial resistance to glucagon-like peptide 1 in diabetes. Diabetes Care 2011, 34:697-702.
3. Nyström T., Gutniak M.K., Zhang Q., et al. Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am J Physiol Endocrinol Metab 2004, 287:E1209-E1215.
4. Ban K., Noyan-Ashraf M.H., Hoefer J., et al. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation 2008, 117:2340-2350.
5. Noyan-Ashraf M.H., Momen M.A., Ban K., et al. GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice. Diabetes 2009, 58:975-983.
6. Deacon C.F., Johnsen A.H., Holst J.J. Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J Clin Endocrinol Metab 1995, 80:952-957.
7. Kieffer T.J., McIntosh C.H., Pederson R.A. Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology 1995, 136:3585-3596.
8. Nikolaidis L.A., Mankad S., Sokos G.G., et al. Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation 2004, 109:962-965.
9. Sokos G.G., Nikolaidis L.A., Mankad S., Elahi D., Shannon R.P. Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. J Card Fail 2006, 12:694-699.
10. Liu H., Dear A.E., Knudsen L.B., Simpson R.W. A long-acting glucagon-like peptide-1 analogue attenuates induction of plasminogen activator inhibitor type-1 and vascular adhesion molecules. J Endocrinol 2009, 201:59-66.
11. Gaspari T., Hongbin Liu Welungoda I., Yunshan Hu Widdop R.E., et al. A GLP-1 receptor agonist liraglutide inhibits endothelial cell dysfunction and vascular adhesion molecule expression in an ApoE-/- mouse model. Diab Vasc Dis Res 2011, 8:117-124.
12. Oeseburg H., de Boer R.A., Buikema H., et al. Glucagon-like peptide 1 prevents reactive oxygen species-induced endothelial cell senescence through the activation of protein kinase A. Arterioscler Thromb Vasc Biol 2010, 30:1407-1414.
13. Ino J., Kojima C., Osaka M., Nitta K., Yoshida M. Dynamic observation of mechanically injured mouse femoral artery reveals an antiinflammatory effect of renin inhibitor. Arterioscler Thromb Vasc Biol 2009, 29:1858-1863.
14. Gao L., Mann G.E. Vascular NAD(P)H oxidase activation in diabetes: a double-edged sword in redox signalling. Cardiovasc Res 2009, 82:9-20.
15. Lin R.Z., Wang T.P., Hung R.J., et al. Tumor-induced endothelial cell apoptosis: roles of NAD(P)H oxidase-derived reactive oxygen species. J Cell Physiol 2011, 226:1750-1762.
16. Geraldes P., King G.L. Activation of protein kinase C isoforms and its impact on diabetic complications. Circ Res 2010, 30(106):1319-1331.
17. Ross D., Joyner W.L. Resting distribution and stimulated translocation of protein kinase C isoforms alpha, epsilon and zeta in response to bradykinin and TNF in human endothelial cells. Endothelium 1997, 5:321-332.
18. Schütze S., Nottrott S., Pfizenmaier K., Krönke M. Tumor necrosis factor signal transduction, cell-type-specific activation and translocation of protein kinase C. J Immunol 1990, 144:2604-2608.
19. Chen C.C., Liau C.S., Lee Y.T. Tumor necrosis factor-alpha, platelet-activating factor, and hydrogen peroxide activate protein kinase C subtypes alpha and epsilon in human saphenous vein endothelial cells. J Cardiovasc Pharmacol 1996, 28:240-244.
20. Inoguchi T., Sonta T., Tsubouchi H., et al. Protein kinase C-dependent increase in reactive oxygen species (ROS) production in vascular tissues of diabetes: role of vascular NAD(P)H oxidase. J Am Soc Nephrol 2003, 14(8 Suppl. 3):S227-S232.
21. Hattori Y., Jojima T., Tomizawa A., et al. A glucagon-like peptide-1 (GLP-1) analogue, liraglutide, upregulates nitric oxide production and exerts anti-inflammatory action in endothelial cells. Diabetologia 2010, 53:2256-2263.
22. Sun W., Yang J. Molecular basis of lysophosphatidic acid-induced NF-κB activation. Cell Signal 2010, 22:1799-1803.
23. Gloire G., Legrand-Poels S., Piette J. NF-kappaB activation by reactive oxygen species: fifteen years later. Biochem Pharmacol 2006, 30(72):1493-1505.
24. Kume N., Mitsuoka H., Hayashida K., Tanaka M. Pentraxin 3 as a biomarker for acute coronary syndrome: comparison with biomarkers for cardiac damage. J Cardiol 2011, 58:38-45.
25. Latini R., Maggioni A.P., Peri G., et al. Lipid Assessment Trial Italian Network (LATIN) Investigators. Prognostic significance of the long pentraxin PTX3 in acute myocardial infarction. Circulation 2004, 19(110):2349-2354.
26. Kotooka N., Inoue T., Fujimatsu D., et al. Node K.Pentraxin3 is a novel marker for stent-induced inflammation and neointimal thickening. Atherosclerosis 2008, 197:368-374.
27. Matsubara J., Sugiyama S., Nozaki T., et al. Pentraxin 3 is a new inflammatory marker correlated with left ventricular diastolic dysfunction and heart failure with normal ejection fraction. J Am Coll Cardiol 2011, 15(57):861-869.
28. Kotooka N., Inoue T., Aoki S., et al. Prognostic value of pentraxin 3 in patients with chronic heart failure. Int J Cardiol 2008, 130(1):19-22. 30.
29. Hill A.L., Lowes D.A., Webster N.R., et al. Regulation of pentraxin-3 by antioxidants. Br J Anaesth 2009, 103:833-839.